was upgraded at Bank of America/Merrill Lynch from underperform to buy. $27 price target. Company is leveraged to improved chicken and beef fundamentals, BofA/Merrill Lynch said.
was downgraded at MKM Partners to neutral. $77 price target. New product growth will likely decelerate in 2013, MKM Partners said.
VMWare was downgraded at Wunderlich to hold. $75 price target. Company materially lowered its near-term guidance, Wunderlich said.
VMWare was downgraded at Sterne Agee to neutral. $86 price target. Company lacks near-term catalysts, Sterne Agee said.
VMWare was downgraded at Morgan Stanley to equal-weight. Company is facing a lengthy transition period, Morgan Stanley said.
VMWare was downgraded at Piper Jaffray to neutral. $90 price target. Company offered disappointing revenue guidance, Piper Jaffray said.
STOCK COMMENTS / EPS CHANGES
target raised at Oppenheimer to $49, Oppenheimer said. Positioned to benefit from structural changes. Outperform rating.
numbers raised at Jefferies. Shares of BIIB now seen reaching $187, Jefferies said. Estimates also raised on strong 2013 outlook. Buy rating.
(CAT - Get Report)
target raised at Jefferies to $95, Jefferies said. Orders have bottomed in 4Q. Hold rating.
numbers raised at UBS. Shares of DNKN now seen reaching $41, UBS said. Estimates also increased on faster than expected acceleration of unit development. Buy rating.
estimates, target boosted at Credit Suisse. Shares of FB now seen reaching $31, according to Credit Suisse. Estimates also upped, as the company is seeing better mobile monetization. Neutral rating.
numbers raised at Oppenheimer. Shares of HON now seen reaching $80, Oppenheimer said. Estimates also raised on growing margins. Outperform rating.
numbers raised at Citigroup. Shares of HSY now seen reaching $89, Citigroup said. Significant upside to consensus 2013 EPS exists.
estimates, target cut at Credit Suisse. Shares of ILMN now seen reaching $59, according to Credit Suisse. Estimates also reduced, as the company lowered its guidance.
numbers raised at UBS. Shares of MMM now seen reaching $110, UBS said. Estimates also increased on solid 4Q organic growth. Buy rating.
numbers raised at Oppenheimer. Shares of ROP now seen reaching $130, Oppenheimer said. Estimates also raised on operating leverage. Outperform rating.